Combined, the Directors of the Human Immunology and Immunotherapy Initiative are leaders in the fields of tolerance and autoimmunity, allergy and clinical immunology, and cancer biology. Briefly, the work in the laboratory of John Cambier is currently focused on problems related to tolerance and autoimmunity, with specific focus on the basis of antigen unresponsiveness of anergic B cells, and mechanisms underlying loss of anergy leading to autoimmune disorders such as Systemic Lupus Erythematosus, Type 1 Diabetes and Rheumatoid Arthritis. The laboratory of Andrew Fontenot is focused on the role of T cells in the development of lung disease, with particular interest in determining the mechanism by which CD4+ T cells recognize and become sensitized to specific antigens that have been shown to play a role in the progression of lung disease. Terry Fry's research program focuses on the use of cell-based immunotherapy for pediatric leukemia. He is principal investigator on a first-in human clinical trial using a novel CD22-targeted chimeric antigen receptor that has induced remissions in 75% of patients with refractory acute lymphoblastic leukemia (ALL). His laboratory has developed two novel chimeric antigen receptor (CAR) constructs that will soon enter clinical trials including a CD19/CD22 bispecific CAR as well as a CAR targeting TSLPR, an oncogene in B cell-ALL. In addition to direct translational research, efforts in Dr. Fry’s laboratory are focused on studying immune biology associated with CAR T cell immunotherapy and mechanisms of leukemia resistance. The overarching goal of these basic and translational efforts are to improve the response rate and durability of remissions in children with high-risk acute lymphoblastic leukemia.
More detailed descriptions of their expertise, research programs, and publications can be found by clicking on the individual directors names below.
Terry J. Fry, MD,
Hematology/Oncology/Bone Marrow Transplant, Children's Hospital Colorado